论文部分内容阅读
目的:探讨血管内皮生长因子受体FLK1和肺耐药蛋白LRP基因在肺癌发生发展过程中的作用。方法:用免疫组化技术(ABC法)对原发性肺癌组织中二种基因的表达进行检测。结果:70例肺癌中,非小细胞肺癌LRP过度表达率为69.5%,明显高于小细胞肺癌LRP过度表达率27.3%(P<0.05);腺癌中LRP的表达明显高于鳞癌(P<0.05)。LRP与FLK1在59例NSCLC中共同表达29例(49.2%),LRP的表达与肺癌的组织学分级、吸烟以及组织学类型有关;FLK1与TNM分期相关,均有统计学意义(P<0.05)。FLK1+LRP、中药治疗、复发与患者的预后有关(P<0.05)。结论:FLK1和LRP基因蛋白产物的检测对肺癌患者的诊治和预后评估有积极意义。
Objective: To investigate the role of vascular endothelial growth factor receptor (FLK1) and lung resistance protein (LRP) gene in the development of lung cancer. Methods: The expression of two genes in primary lung cancer was detected by immunohistochemistry (ABC method). Results: In 70 cases of lung cancer, the over expression rate of LRP in non-small cell lung cancer was 69.5%, which was significantly higher than that in small cell lung cancer (27.3%, P <0.05). The expression of LRP in adenocarcinoma was significantly higher than that in squamous cell carcinoma <0.05). There were 29 cases (49.2%) of LRP and FLK1 co-expressed in 59 cases of NSCLC. The expression of LRP was related to histological grade, smoking and histological type of lung cancer. FLK1 was correlated with TNM staging (P <0.05) . FLK1 + LRP, Chinese medicine treatment, recurrence and prognosis of patients (P <0.05). Conclusion: The detection of FLK1 and LRP gene protein products has positive significance in diagnosis and prognosis of patients with lung cancer.